WO2009041663A1 - 皮膚疾患の予防及び／または治療剤 - Google Patents

皮膚疾患の予防及び／または治療剤 Download PDF

Info

Publication number
WO2009041663A1
WO2009041663A1 PCT/JP2008/067563 JP2008067563W WO2009041663A1 WO 2009041663 A1 WO2009041663 A1 WO 2009041663A1 JP 2008067563 W JP2008067563 W JP 2008067563W WO 2009041663 A1 WO2009041663 A1 WO 2009041663A1
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
agent
treatment
skin diseases
formula
Prior art date
Application number
PCT/JP2008/067563
Other languages
English (en)
French (fr)
Inventor
Keisuke Yamamoto
Seiji Aratake
Daisuke Nakashima
Kimihisa Ueno
Mirai Mizutani
Daisuke Harada
Katsuya Kobayashi
Kazuki Hemmi
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Priority to US12/680,484 priority Critical patent/US8729264B2/en
Priority to EP08833967.6A priority patent/EP2206714B1/en
Priority to JP2009534444A priority patent/JP5372763B2/ja
Priority to CN200880118361.9A priority patent/CN101878217B/zh
Publication of WO2009041663A1 publication Critical patent/WO2009041663A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

　式（I） （式中、各記号は本文と同義である。）で表されるピラゾロピリミジン誘導体またはその薬理学的に許容される塩を有効成分として含有する皮膚疾患の予防及び／または治療剤等を提供する。
PCT/JP2008/067563 2007-09-28 2008-09-26 皮膚疾患の予防及び／または治療剤 WO2009041663A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/680,484 US8729264B2 (en) 2007-09-28 2008-09-26 Agent for prevention and/or treatment of skin diseases
EP08833967.6A EP2206714B1 (en) 2007-09-28 2008-09-26 Agent for prevention and/or treatment of skin diseases
JP2009534444A JP5372763B2 (ja) 2007-09-28 2008-09-26 皮膚疾患の予防及び／または治療剤
CN200880118361.9A CN101878217B (zh) 2007-09-28 2008-09-26 皮肤疾病的预防和/或治疗剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007252804 2007-09-28
JP2007-252804 2007-09-28

Publications (1)

Publication Number Publication Date
WO2009041663A1 true WO2009041663A1 (ja) 2009-04-02

Family

ID=40511543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067563 WO2009041663A1 (ja) 2007-09-28 2008-09-26 皮膚疾患の予防及び／または治療剤

Country Status (7)

Country Link
US (1) US8729264B2 (ja)
EP (1) EP2206714B1 (ja)
JP (1) JP5372763B2 (ja)
KR (1) KR20100087298A (ja)
CN (1) CN101878217B (ja)
TW (1) TW200918071A (ja)
WO (1) WO2009041663A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011108689A1 (ja) * 2010-03-05 2011-09-09 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
WO2011137331A2 (en) * 2010-04-30 2011-11-03 Kinentia Biosciences Llc 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
WO2013031931A1 (ja) 2011-09-02 2013-03-07 協和発酵キリン株式会社 ケモカイン受容体活性調節剤
WO2014133182A1 (ja) 2013-03-01 2014-09-04 協和発酵キリン株式会社 眼炎症性疾患の予防及び／または治療剤
WO2017178416A1 (en) 2016-04-15 2017-10-19 Bayer Animal Health Gmbh Pyrazolopyrimidine derivatives
WO2018197401A1 (en) 2017-04-27 2018-11-01 Bayer Animal Health Gmbh New bicyclic pyrazole derivatives

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
KR101426448B1 (ko) * 2012-11-09 2014-08-05 주식회사 엘엠에스 나노 복합체, 이를 포함하는 광학 부재 및 백라이트 유닛
CN104592198A (zh) * 2015-01-21 2015-05-06 湖南华腾制药有限公司 一种2-甲基-5-(哌啶-4-基)嘧啶的制备方法
EP3256585A4 (en) * 2015-02-13 2018-08-15 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN110483526B (zh) * 2019-09-09 2021-10-01 辽宁大学 含芳基腙结构的吡唑并[1,5-a]嘧啶类衍生物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05112571A (ja) * 1990-10-19 1993-05-07 Otsuka Pharmaceut Co Ltd ピリミジン誘導体
JP2002501532A (ja) * 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
WO2002040485A1 (fr) * 2000-11-17 2002-05-23 Ishihara Sangyo Kaisha, Ltd. Medicaments preventifs ou therapeutiques contre le diabete, contenant des composes a heterocycle fusionne ou leurs sels
WO2003091256A1 (fr) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive
WO2004110454A1 (ja) * 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. アデノシンＡ2ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
JP2006520326A (ja) * 2003-02-28 2006-09-07 ハワード フローリー インスティチュート オブ エクスペリメンタル フィジオロジー アンド メディシン 治療薬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360985A (ja) 1986-08-08 1988-03-17 Yoshitomi Pharmaceut Ind Ltd ４，７−ジヒドロピラゾロ〔１，５−ａ〕ピリミジン誘導体
JPH04270285A (ja) * 1988-11-14 1992-09-25 Nissan Chem Ind Ltd ピラゾロピリミジン系メバロノラクトン類
AU639615B2 (en) * 1990-10-09 1993-07-29 Otsuka Pharmaceutical Co., Ltd. Pyrimidine derivative, production thereof, and androgen inhibitor
JPH07157485A (ja) 1993-12-02 1995-06-20 Nkk Corp 縮合ピリミジノン誘導体及びそれらを含有するアンジオテンシンｉｉ拮抗剤
JP3479708B2 (ja) 1995-12-20 2003-12-15 株式会社大塚製薬工場 安息香酸誘導体
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
AU2321000A (en) 1999-01-29 2000-08-18 Sumitomo Chemical Company, Limited Fat accumulation inhibitory agents
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
ATE389656T1 (de) * 2002-06-04 2008-04-15 Neogenesis Pharmaceuticals Inc Pyrazolo(1,5-a)pyrimidin-verbindungen als antivirale agentien
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
ZA200704476B (en) 2004-11-04 2008-09-25 Vertex Pharma Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
JP2009511484A (ja) * 2005-10-06 2009-03-19 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05112571A (ja) * 1990-10-19 1993-05-07 Otsuka Pharmaceut Co Ltd ピリミジン誘導体
JP2002501532A (ja) * 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
WO2002040485A1 (fr) * 2000-11-17 2002-05-23 Ishihara Sangyo Kaisha, Ltd. Medicaments preventifs ou therapeutiques contre le diabete, contenant des composes a heterocycle fusionne ou leurs sels
WO2003091256A1 (fr) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive
JP2006520326A (ja) * 2003-02-28 2006-09-07 ハワード フローリー インスティチュート オブ エクスペリメンタル フィジオロジー アンド メディシン 治療薬
WO2004110454A1 (ja) * 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. アデノシンＡ2ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2206714A4 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011108689A1 (ja) * 2010-03-05 2011-09-09 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
CN102791712B (zh) * 2010-03-05 2015-07-01 协和发酵麒麟株式会社 吡唑并嘧啶衍生物
AU2011221849B2 (en) * 2010-03-05 2015-04-02 Kyowa Kirin Co., Ltd. Pyrazolopyrimidine derivative
CN102791712A (zh) * 2010-03-05 2012-11-21 协和发酵麒麟株式会社 吡唑并嘧啶衍生物
JP5688404B2 (ja) * 2010-03-05 2015-03-25 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
US20130102620A1 (en) * 2010-03-05 2013-04-25 Kyowa Hakko Kirin Co., Ltd. Pyrazolopyrimidine derivative
US8815874B2 (en) 2010-03-05 2014-08-26 Kyowa Hakko Kirin Co., Ltd. Pyrazolopyrimidine derivative
KR101473545B1 (ko) 2010-03-05 2014-12-16 교와 핫꼬 기린 가부시키가이샤 피라졸로피리미딘 유도체
US8859777B2 (en) 2010-04-30 2014-10-14 Kinentia Biosciences Llc 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
WO2011137331A3 (en) * 2010-04-30 2012-04-05 Kinentia Biosciences Llc 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
WO2011137331A2 (en) * 2010-04-30 2011-11-03 Kinentia Biosciences Llc 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
WO2013031931A1 (ja) 2011-09-02 2013-03-07 協和発酵キリン株式会社 ケモカイン受容体活性調節剤
WO2014133182A1 (ja) 2013-03-01 2014-09-04 協和発酵キリン株式会社 眼炎症性疾患の予防及び／または治療剤
WO2017178416A1 (en) 2016-04-15 2017-10-19 Bayer Animal Health Gmbh Pyrazolopyrimidine derivatives
WO2018197401A1 (en) 2017-04-27 2018-11-01 Bayer Animal Health Gmbh New bicyclic pyrazole derivatives
US11130768B2 (en) 2017-04-27 2021-09-28 Bayer Animal Health Gmbh Bicyclic pyrazole derivatives

Also Published As

Publication number Publication date
JPWO2009041663A1 (ja) 2011-01-27
EP2206714A1 (en) 2010-07-14
US20100256134A1 (en) 2010-10-07
US8729264B2 (en) 2014-05-20
EP2206714B1 (en) 2015-01-21
CN101878217B (zh) 2014-01-15
TW200918071A (en) 2009-05-01
CN101878217A (zh) 2010-11-03
KR20100087298A (ko) 2010-08-04
EP2206714A4 (en) 2011-06-01
JP5372763B2 (ja) 2013-12-18

Similar Documents

Publication Publication Date Title
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2009017837A3 (en) Sublingual fentanyl spray
WO2007087431A3 (en) Sublingual fentanyl spray
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2007135527A3 (en) Benzimidazolyl compounds
WO2011028947A3 (en) Heterocyclic compounds for the inhibition of pask
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
EP2340821A4 (en) PROPHYLAXIS AGENTS / ADULTS OF ADULT DISEASES WITH 5-AMINOLEVULINIC ACID, A 5-AMINOLEVULIC ACID DERIVATIVE OR 5-AMINOLEVULIC ACID SALT OR 5-AMINOLEVULIC ACID DERIVATIVE AS AN ACTIVE SUBSTANCE
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2009078447A1 (ja) 抗ノロウイルス剤、抗インフルエンザウイルス剤、およびこれらを用いた抗ウイルス処理方法
TN2012000092A1 (en) Therapeutic agent for mood disorders
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
EP2196206B8 (en) Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2012119046A3 (en) Heterocyclic compounds for the inhibition of pask
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880118361.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08833967

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009534444

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12680484

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008833967

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107009314

Country of ref document: KR

Kind code of ref document: A